Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Rondecabtagene autoleucel |
| Trade Name | |
| Synonyms | IMPT 314|IMPT314|IMPT-314|ronde-cel|LYL314|LYL 314|LYL-314 |
| Drug Descriptions |
Rondecabtagene autoleucel comprises autologous naive/memory-enriched T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and CD20 and containing a TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (Blood (2023) 142 (Supplement 1): 6892). |
| DrugClasses | CD19 Immune Cell Therapy 73 CD20 Immune Cell Therapy 15 |
| CAS Registry Number | NA |
| NCIT ID | C199659 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Rondecabtagene autoleucel | Rondecabtagene autoleucel | 0 | 2 |